PT2208070E - Testes de diagnóstico, preditivos e de prognóstico para o cancro - Google Patents

Testes de diagnóstico, preditivos e de prognóstico para o cancro

Info

Publication number
PT2208070E
PT2208070E PT88401393T PT08840139T PT2208070E PT 2208070 E PT2208070 E PT 2208070E PT 88401393 T PT88401393 T PT 88401393T PT 08840139 T PT08840139 T PT 08840139T PT 2208070 E PT2208070 E PT 2208070E
Authority
PT
Portugal
Prior art keywords
predictive
diagnostic
cancer
prognostic tests
prognostic
Prior art date
Application number
PT88401393T
Other languages
English (en)
Portuguese (pt)
Inventor
Kai Stoeber
Gareth Hayden Williams
Original Assignee
Cambridge Cancer Diagnostics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cambridge Cancer Diagnostics Ltd filed Critical Cambridge Cancer Diagnostics Ltd
Publication of PT2208070E publication Critical patent/PT2208070E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PT88401393T 2007-10-15 2008-10-15 Testes de diagnóstico, preditivos e de prognóstico para o cancro PT2208070E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0720113.0A GB0720113D0 (en) 2007-10-15 2007-10-15 Diagnostic, prognostic and predictive testing for cancer

Publications (1)

Publication Number Publication Date
PT2208070E true PT2208070E (pt) 2013-01-08

Family

ID=38813827

Family Applications (1)

Application Number Title Priority Date Filing Date
PT88401393T PT2208070E (pt) 2007-10-15 2008-10-15 Testes de diagnóstico, preditivos e de prognóstico para o cancro

Country Status (11)

Country Link
US (3) US8512716B2 (https=)
EP (1) EP2208070B1 (https=)
JP (2) JP5559056B2 (https=)
CN (1) CN101896819A (https=)
AU (1) AU2008313459B2 (https=)
CA (1) CA2702653A1 (https=)
DK (1) DK2208070T3 (https=)
ES (1) ES2395890T3 (https=)
GB (1) GB0720113D0 (https=)
PT (1) PT2208070E (https=)
WO (1) WO2009050461A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0921873D0 (en) * 2009-12-15 2010-01-27 Cytosystems Ltd Assay
WO2012012693A2 (en) * 2010-07-23 2012-01-26 President And Fellows Of Harvard College Methods for detecting signatures of disease or conditions in bodily fluids
AU2013388864B2 (en) * 2013-05-09 2017-06-08 The Procter & Gamble Company Method and system for assessing health condition
CN103592444A (zh) * 2013-11-27 2014-02-19 中国人民解放军沈阳军区总医院 一种检测乳腺癌中cyclin G1蛋白表达并进行预后评估的方法
US9857354B2 (en) 2014-06-01 2018-01-02 Novazoi Theranostics, Inc. Compositions and methods for prognosis and treatment of neoplasm
WO2016131875A1 (en) * 2015-02-17 2016-08-25 Biontech Diagnostics Gmbh Methods and kits for the molecular subtyping of bladder cancer
CN107771285A (zh) 2015-06-08 2018-03-06 阿奎尔诊断有限公司 方法
EP4060344A1 (en) 2015-06-08 2022-09-21 Arquer Diagnostics Limited Methods and kits
CN105986034A (zh) * 2016-06-15 2016-10-05 南京卡迪睿伯生物技术有限公司 一组胃癌基因的应用
CN108344867B (zh) * 2018-01-23 2020-05-15 郑州大学第一附属医院 人组蛋白H3 Ser10和Ser28在鉴定人卵母细胞成熟分期中的应用
CN108344868B (zh) * 2018-01-23 2020-05-15 郑州大学第一附属医院 人组蛋白H3 Ser10和Ser28在鉴定人早期胚胎的发育分期中的应用
CN111187833A (zh) * 2018-11-14 2020-05-22 上海生物芯片有限公司 Plk1和bub1b基因联合作为肺癌生物标志物的用途
GB201820867D0 (en) * 2018-12-20 2019-02-06 Arquer Diagnostics Ltd Detection method
CN109988708B (zh) * 2019-02-01 2022-12-09 碳逻辑生物科技(中山)有限公司 一种用于对患有结肠直肠癌的患者进行分型的系统
CN110846413B (zh) * 2019-11-23 2023-05-26 中南大学湘雅三医院 Mafg/mafg-as1/mafg正反馈环作为靶位点检测试剂的应用
CN114019163B (zh) * 2021-11-02 2024-07-23 复旦大学附属中山医院 基于活化b细胞表达的结肠癌预后诊断用标记物及其用途
WO2023150578A2 (en) * 2022-02-01 2023-08-10 4D Path Inc. Systems and methods for image-based disease characterization

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4329177A1 (de) * 1993-08-30 1995-03-02 Chemotherapeutisches Forschungsinstitut Georg Speyer Haus Klonierung eines neuen Mitgliedes der Familie der Serin-Threonin-Kinasen
DE19915057A1 (de) 1999-04-01 2000-10-19 Forschungszentrum Borstel Monoklonale Antikörper gegen das humane Mcm3 Protein, Verfahren zu ihrer Herstellung und ihre Verwendung
EP1422526A1 (en) 2002-10-28 2004-05-26 MTM Laboratories AG Method for improved diagnosis of dysplasias
US20040231909A1 (en) * 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
GB0323225D0 (en) * 2003-10-03 2003-11-05 Ncc Technology Ventures Pte Lt Materials and methods relating to breast cancer classification
CA2563074C (en) * 2004-04-09 2014-05-20 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
CA2563168A1 (en) * 2004-04-14 2005-11-17 President And Fellows Of Harvard College Nucleic-acid programmable protein arrays
EP1805676A1 (en) * 2004-09-22 2007-07-11 Tripath Imaging, Inc. Methods and computer program products for analysis and optimization of marker candidates for cancer prognosis
ATE464395T1 (de) * 2005-02-18 2010-04-15 Astrazeneca Ab Verfahren zur bestimmung der reaktionsfähigkeit gegenüber chk1-inhibitoren
EP1968579A1 (en) * 2005-12-30 2008-09-17 Astex Therapeutics Limited Pharmaceutical compounds
ATE456053T1 (de) * 2005-12-30 2010-02-15 Ventana Med Syst Inc Na+, k+-atpase-expression bei zervixdysplasie und krebs

Also Published As

Publication number Publication date
US8512716B2 (en) 2013-08-20
CN101896819A (zh) 2010-11-24
US20140154680A1 (en) 2014-06-05
CA2702653A1 (en) 2009-04-23
EP2208070A1 (en) 2010-07-21
GB0720113D0 (en) 2007-11-28
DK2208070T3 (da) 2012-12-17
US20180223366A1 (en) 2018-08-09
JP2014095726A (ja) 2014-05-22
AU2008313459A1 (en) 2009-04-23
ES2395890T3 (es) 2013-02-15
JP5837630B2 (ja) 2015-12-24
US20100285474A1 (en) 2010-11-11
EP2208070B1 (en) 2012-10-03
WO2009050461A1 (en) 2009-04-23
JP5559056B2 (ja) 2014-07-23
AU2008313459B2 (en) 2013-01-24
JP2011501809A (ja) 2011-01-13

Similar Documents

Publication Publication Date Title
PT2208070E (pt) Testes de diagnóstico, preditivos e de prognóstico para o cancro
BRPI0818801A2 (pt) Sistema de testes de diagnóstico.
BRPI0716944A2 (pt) biomarcadores de modulaÇço alvo, eficÁcia, diagnàstico, e/ou prognàstico para inibidores de raf
BRPI0914969A2 (pt) método para diagnóstico de cânceres que expressam o receptor de her2 ou suas variantes truncadas
DK2115472T3 (da) Cancerbiomarkører
EP2009611A4 (en) ROAD SHARING LINE DETECTOR
BRPI0910608A2 (pt) métodos e sistemas para avaliar resultados clínicos
EP1846576A4 (en) BIOMARKERS OF TISSUE STATUS
EP2007651A4 (en) LOW PRESSURE SAMPLE SAMPLING DEVICE
BRPI0813002A2 (pt) marcadores preditivos para o câncer ovariano
DK3567363T3 (da) Prøvningsindretninger, -fremgangsmåder og reagenser
BRPI0923159A2 (pt) gene de delta-endotoxina axmi-150 e métodos para sua utilização.
ATE405436T1 (de) Hebel für ringordnermechanismus
BRPI0820721A2 (pt) Reagentes e métodos para detectar analitos
BRPI1015922A2 (pt) sistemas e métodos para testar analitos
EP2089722A4 (en) BIOMARKERS
EP2208072A4 (en) FORECAST PROCEDURES
EP2087152A4 (en) ENDOMETRIAL BIOMARKERS
BRPI0807768A2 (pt) Nova sialidase.
BRPI0918048A2 (pt) configuração de dispositivo adaptado para testes
EP1934603A4 (en) BIOMARKER FOR PROSTATE CANCER
BRPI0912982A2 (pt) métodos, dispositivos, kits e composições para detectar nematódeos
BRPI0814645A2 (pt) Métodos e composições para tratar de doença autoimune.
BRPI1009460A2 (pt) domínio de ligação do anticorpo, anticorpo, uso de um domínio de ligação ou anticorpo, método para detectar a presença de células cancerígenas em uma amostra.
BRPI0907010A2 (pt) Análise para o diagnóstico de streptococcus pneumoniae